학술논문
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
Document Type
article
Author
The OpenSAFELY Collaborative; Amelia Green; Helen Curtis; William Hulme; Elizabeth Williamson; Helen McDonald; Krishnan Bhaskaran; Christopher Rentsch; Anna Schultze; Brian MacKenna; Viyaasan Mahalingasivam; Laurie Tomlinson; Alex Walker; Louis Fisher; Jon Massey; Colm Andrews; Lisa Hopcroft; Caroline Morton; Richard Croker; Jessica Morley; Amir Mehrkar; Seb Bacon; David Evans; Peter Inglesby; George Hickman; Tom Ward; Simon Davy; Rohini Mathur; John Tazare; Rosalind Eggo; Kevin Wing; Angel Wong; Harriet Forbes; Chris Bates; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre
Source
BMC Medicine, Vol 20, Iss 1, Pp 1-14 (2022)
Subject
Language
English
ISSN
1741-7015
Abstract
Abstract Background While the vaccines against COVID-19 are highly effective, COVID-19 vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing the characteristics of individuals who have experienced COVID-19 vaccine breakthroughs could be hugely important in helping to determine who may be at greatest risk. Methods With the approval of NHS England, we conducted a retrospective cohort study using routine clinical data from the OpenSAFELY-TPP database of fully vaccinated individuals, linked to secondary care and death registry data and described the characteristics of those experiencing COVID-19 vaccine breakthroughs. Results As of 1st November 2021, a total of 15,501,550 individuals were identified as being fully vaccinated against COVID-19, with a median follow-up time of 149 days (IQR: 107–179). From within this population, a total of 579,780 (